Fatty acid derivatives of clozapine: Prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat

Neuropsychopharmacology

Volumn 24, Issue 1, 2001, Pages 55-65

  Baldessarini, Ross J ^a,b,d   Campbell, Alexander ^a,b   Webb, Nigel L ^c   Swindell, Charles S ^c   Flood, James G ^a,b   Shashoua, Victor E ^a,b   Kula, Nora S ^a,b   Hemamalini, S ^c   Bradley, Matthews O ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Protarga Inc   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Blood brain barrier; Clozapine; Docosahexaenoic acid; Dopamine; Fatty acids; Linoleic acid; Myristic acid; Oleic acid; Palmitic acid

Indexed keywords

APOMORPHINE; CLOZAPINE; CLOZAPINE DERIVATIVE; DOCOSAHEXAENOYLCLOZAPINE; DOPAMINE RECEPTOR; N LINOLEOYLCLOZAPINE; N MYRISTOYLCLOZAPINE; N OLEOYLCLOZAPINE; N PALMITOYLCLOZAPINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AROUSAL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RAT; RECEPTOR AFFINITY;

AMIDES; ANIMALS; APOMORPHINE; AROUSAL; BRAIN; CATALEPSY; CLOZAPINE; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE;

EID: 0035205332     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00173-1     Document Type: Article

References (35)

1. Clozapine-induced agranulocytosis: Incidence and risk factors in the US
2. Linoleic acid passage through the blood-brain barrier and a possible effect of age
3. Clozapine - A novel antipsychotic agent
4. Tissue concentrations of clozapine and its metabolites in the rat
5. Effects of medical interventions on suicidal behavior: Summary and conclusions
6. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system
7. Biochemical and nutritional aspects of the metabolism of polyunsaturated fatty acids and phospholipids in experimental models of retinal degenerations
8. Risperidone vs clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind trial
9. Dose-catalepsy response to haloperidol in rat: Effects of gender and strain
10. Bromocriptine antagonizes behavioral effects of cocaine in the rat
11. R(-) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: Central dopaminergic behavioral activity in the rat
12. Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine
13. Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of the rat forebrain
14. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with clozapine and fluoxetine or valproate
15. A new function for the LDL receptors: Transcytosis of LDL across the blood-brain barrier
16. New antipsychotics: Classification, efficacy and adverse effects
17. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
18. Essential fatty acids in growth and development
19. Synthesis, brain uptake and pharmacological properties of lipid esters of γ-aminobutyric acid
20. Pharmacokinetics and pharmacodynamics of clozapine
21. Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine
22. 4 receptor-selective ligand
23. 4 receptor-selective ratioligands
24. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
25. Changing fatty acid content of growth cone lipids prior to synaptogenesis
26. Developmental maturation of hepatic n-3 polyunsaturated fatty acid metabolism: Supply of docosahexaenoic acid to retina and brain
27. Suicide in schizophrenia: Risk factors and clozapine treatment
28. Membrane docosahexaenoate is supplied to the developing brain and liver by the liver
29. N-docosahexaenoyl-3-hydroxytyramine: A dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite
30. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease
31. Fatty acid transport through the blood-brain barrier
32. Omega-3 fatty acids in bipolar disorder
33. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography
34. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
35. Clozapine-induced seizures and EEG changes